Prelude Capital Management, LLC Intercept Pharmaceuticals, Inc. Transaction History

Prelude Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$9.99 - $18.71 $627,841 - $1.18 Million	62,847 New	62,847 $1.17 Million
Q4 2020 Feb 16, 2021	BUY	$24.48 - $42.47 $338,558 - $587,360	13,830 New	13,830 $342,000
Q4 2019 Feb 14, 2020	SELL	$57.36 - $124.1 $8,661 - $18,739	-151 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$58.69 - $80.46 $176 - $241	-3 Reduced 1.95%	151 $10,000
Q2 2019 Aug 14, 2019	SELL	$77.77 - $120.68 $1,555 - $2,413	-20 Reduced 11.49%	154 $12,000

Q1 2019 May 15, 2019	BUY	$91.83 - $120.68 $9,274 - $12,188	101 Added 138.36%	174 $19,000
Q3 2018 Nov 14, 2018	SELL	$88.49 - $127.55 $1.16 Million - $1.67 Million	-13,070 Reduced 99.44%	73 $9,000
Q2 2018 Aug 14, 2018	BUY	$60.0 - $85.67 $788,580 - $1.13 Million	13,143 New	13,143 $1.1 Million
Q4 2017 Feb 14, 2018	SELL	$58.2 - $72.76 $102,082 - $127,621	-1,754 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$57.01 - $118.75 $99,995 - $208,287	1,754	1,754 $102,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.